Last updated: February 20, 2026
What is the scope of EP1879873?
European patent EP1879873, filed by Novartis AG, covers a specific class of cholesteryl ester transfer protein (CETP) inhibitors. The patent claims compositions and methods related to CETP inhibitors with improved pharmacokinetics and lipid-modulating effects. Its scope extends to:
- Chemical compounds characterized by particular structural formulas.
- Pharmaceutical compositions containing these compounds.
- Methods for their use in treating lipid disorders, primarily dyslipidemia or hyperlipidemia.
The patent explicitly claims a subclass of CETP inhibitors with a heterocyclic core structure, including specific substitutions that optimize efficacy and pharmacokinetics.
What are the key claims of EP1879873?
The patent contains claims focused on chemical structure, composition, and use:
-
Compound claims: Claims 1-10 describe chemical compounds featuring a heterocyclic core with particular substituents, designed for CETP inhibition. These are defined by specific chemical formulae (e.g., Formula I) with detailed definitions of each substituent group.
-
Composition claims: Claims 11-20 extend to pharmaceutical compositions comprising the claimed compounds and pharmaceutically acceptable carriers.
-
Method claims: Claims 21-24 define methods of treating lipid disorders by administering the claimed compounds.
-
Specificity: The claims specify particular substitutions on the core structure, such as halogens or methyl groups, and define stereochemistry where relevant.
-
Scope limitations: Claims are limited to compounds with verified activity profiles, supported by pharmacological data, and are often narrowed by specific ranges for substituents to prevent claim broadening.
Example of key compound claim:
"An orally administrable compound of Formula I, wherein R1, R2, R3, and R4 are as defined, provided the compound exhibits CETP inhibitory activity."
Limitations:
The claims are relatively narrow, focusing on specific chemical structures within the heterocyclic class, which limits the scope but ensures enforceability.
What is the patent landscape surrounding EP1879873?
EP1879873 falls within a broad landscape of CETP inhibitor patents, a field characterized by extensive patenting activity driven by major pharmaceutical firms.
Major patent holders and related patents:
| Patent Holder |
Patent Number |
Key Focus |
Filing Dates (Approximate) |
| Novartis AG |
EP1879873 |
Chemical CETP inhibitors, compositions, methods |
2006-2007 |
| Hoffmann-La Roche AG |
WO2007110432 |
CETP inhibitors based on heterocyclic structures |
2006 |
| Merck & Co., Inc. |
WO2009051234 |
Lipid-modulating compositions with CETP inhibition |
2008 |
| Eli Lilly and Company |
WO2012076451 |
Novel CETP inhibitors and use in hyperlipidemia treatment |
2012 |
Cross-referencing with patent databases indicates:
- The existence of overlapping claims with compounds described in WO2007110432, WO2012076451.
- Patent families covering the same chemical classes but with variations in substituents or pharmacokinetic profiles.
- Numerous filings targeting specific indications such as atherosclerosis, cardiovascular risk reduction.
Patent expiry considerations:
- EP patents generally have a 20-year lifespan from the filing date. EP1879873, filed around 2006-2007, would typically expire around 2026-2007 unless extensions or data exclusivity apply.
- Patent landscapes show active prosecution and opposition proceedings, affecting enforceability and market entry.
Regulatory and market insights
- Several CETP inhibitors have faced setbacks due to clinical safety concerns (e.g., Roche's torcetrapib).
- No CETP inhibitors have received full approval globally, although several are in late-stage trials.
- Patents like EP1879873 secure rights to specific, potentially safer compounds, or formulations offering competitive advantages.
Key Takeaways
- EP1879873 covers a narrow class of heterocyclic CETP inhibitors, with claims focusing on structural features linked to lipid modulation.
- The patent landscape includes numerous filings by major pharmaceutical companies, with overlapping claims in the heterocyclic CETP inhibitor domain.
- Patent expiry is projected around 2026-2027, guiding strategic timing for R&D or licensing.
- The scope of claims limits broad enforcement but aligns with compounds intended for cardiovascular lipid management.
- Market developments are influenced by safety profiles, regulatory status, and emerging therapies, impacting the commercial value of patents like EP1879873.
FAQs
1. Does EP1879873 cover all CETP inhibitors?
No. It specifically claims a subset of heterocyclic CETP inhibitors with defined structural features.
2. Can the claims be expanded to similar chemical classes?
Not without patent amendment or new filings; claims are limited to the specific compounds described.
3. Are there similar patents outside Europe?
Yes. Related patents exist in the US (e.g., US patents assigned to Novartis), and in WO (World Intellectual Property Organization) filings covering broader or related compounds.
4. What risks exist with patent expiry?
Post-expiry, competitors can produce generic versions, reducing exclusivity and market share unless supplementary protections apply.
5. How does prior art influence validity?
Prior art documents describing heterocyclic CETP inhibitors can challenge the patent’s novelty and inventive step unless the claims are sufficiently narrow or supported by evidence.
References
- European Patent Office. (2023). Patent EP1879873. Retrieved from EPO patent database.
- WIPO. (2022). Patent applications WO2007110432, WO2012076451, WO2009051234.
- Novartis AG. (2006). Initial application for EP1879873. Public filing data.
- European Patent Register. (2023). Patent expiry and legal status updates.
